Search Results

BioAgilytix Labs, LLC today announces the appointment, effective immediately, of Euan Menzies as Chairman and CEO. Jim Datin is retiring from his executive management role.

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that it signed a formal, worldwide partnership agreement with global contract research organization Clinical Trial and Consulting Services (CTI).

BioAgilytix Labs, LLC announced today that it signed a definitive agreement to acquire MicroConstants, adding it to its family of companies.

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that, following Australian Foreign Investment Review Board (“FIRB”) approval, it officially closed the purchase of 360biolabs®.

MicroConstants, Inc., a leader in bioanalytical testing services, announced that it has signed an agreement with BioAgilytix Labs, a leading global contract research organization (CRO) focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development.

BioAgilytix welcomes Amanda L. Hays , Ph.D. to its team as Scientific Officer.

CTI Clinical Trial & Consulting Services (CTI), a global contract research organization (CRO) specializing in personalized curative therapies and complex clinical programs, announces that it signed a formal, worldwide partnership agreement with BioAgilytix, a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development.

BioAgilytix Labs, LLC, a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia.

BioAgilytix, a leading global contract research organization, announced an agreement to be further capitalized by Cinven, a leading international private investment firm focused on building world-class global companies.

BioAgilytix is thrilled to announce the addition of a new diagnostics tool to their growing list of cutting-edge bioanalysis instruments. The Phadia™ 200 is a powerhouse of a machine, in a compa